Last month, pharma’s R&D leaders gathered for the 6th annual clinical trial supply Europe event. The event’s active format with its 100% interactive agenda fueled the discussions of the day to ensure the take-home value from the event was maximized.
Twenty years ago, the US was facing enormous pressure to find a way to address the issue of hazardous waste, including batteries that contained “metals of concern” as classified under the Resource Conservation and Recovery Act (RCRA) of 1976. States were charged with implementing the Act and passed various pieces of inconsistent and complex legislation. The Battery Act in 1996 eased some of these issues, classifying certain batteries as universal waste and superseding state-passed legislation. In this Act, the authors envisioned that industry would establish recycling programs to deal with the most problematic battery chemistries.
Last month, the MHRA informed the industry of the latest updates experienced by the agency as well as the regulatory hurdles that are on the horizon for the industry
Terrorism, climate change and financial stability are not the only globally-critical areas where there is a huge need for greater co-operation and interaction between independent agencies with common needs and objectives. In a world increasingly characterised by division, alienation and conflict, corporate organisations are being urged to work in a more concerted way towards their common goals. Alan Kennedy looks at the upsides and downsides of closer collaboration in the field of pharma-logistics.
Opportunity almost always comes with risk—and that's especially true for life sciences companies looking at new markets for new value. While globalization can be a means for driving value, JLL’s Life Sciences Outlook calls it a "high risk" strategy from a real estate and facilities perspective. In this Q&A, Roger Humphrey, Executive Managing Director, JLL Life Sciences, talks candidly about the risks associated with seizing that opportunity.
Last week a select collection of CRISPR Cas9 enthusiasts gathered to debate both the bright future and the flaring issues facing the technique, which has trailblazed its way through the market.
The event starred representatives for two key CRISPR Cas9 influencers – Dr Doudna & Dr Zhang. The representatives divulged their experiences in working alongside the biologists who are both recognised as key players within the CRISPR arena.
With there being a 12.8 billion Euro deficit in France’s 2015 budget, the French government announced on 24th September plans for the Projet de Loi de Financement de la Sécurité Sociale 2016 (PLFSS; Social Security Finance Bill 2016). For the second consecutive year, the PFLSS cost-containment measures include a heavy focus on drug expenditure as part of the government’s strategy to bring down the debt.
With there being a 12.8 million Euro deficit in France’s 2015 budget, the French government announced on 24 th September plans for the Projet de Loi de Financement de la Sécurité Sociale 2016 (PLFSS; Social Security Finance Bill 2016). For the second consecutive year, the PFLSS cost-containment measures include a heavy focus on drug expenditure as part of the...
As discussions circled around the concept of women in science feeling ‘imposter syndrome’ in what many perceive as a male dominated industry, at this month’s Biobeat 15, Professor Dame Sally Davies, Chief Medical Officer for England hailed the need for more female senior level scientists in the UK. She also noted that the Department of Health is due to issue a substantial grant to a robotic biosample repository located in the South of England.
Earlier this month, MHRA pharmacovigilance inspectors and industry members gathered to interact and discuss how to develop industry best practice and catch the latest on any legislation updates in the pipeline.